New Study Cites a Possible Breakthrough Treatment In Pain Management

Precise cold exposures can regenerate damaged nerves, offering hope following traumatic injury

Pain Management: Damaged nerves can be regenerated with the application of a frozen needle under advanced imaging guidance, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston.

The technique, called interventional cryoneurolysis, is performed by an interventional radiologist and can offer hope to patients in persistent pain following a traumatic injury.

“The idea that we can induce regeneration of damaged nerves simply by placing a cold needle through the skin under imaging guidance is extremely exciting,” said the lead author of the study, J. David Prologo, MD, FSIR, ABOM-D, an interventional radiologist and associate professor at Emory University School of Medicine in Atlanta. “This research answers the call from United States legislators and specialty medical societies to develop alternatives to opioids for the management of pain.”

Researchers at Emory University treated eight patients with chronic nerve pain related to a prior trauma with CT-guided interventional cryoneurolysis. CT-guided cryoneurolysis uses imaging to place a needle and freeze damaged nerves, causing them to degenerate and lose function. “What happens next is almost magical,” Prologo says. “If the nerve is exposed to the correct amount of cold, over the correct area, for the right amount of time, it will regenerate—replacing the previously damaged nerve with a healthy one.”

In this study, the average time from traumatic injury to the procedure was 9.5 years. There were no procedure related complications or adverse events, and all patients returned to their baseline strength over time—confirming regeneration of the targeted nerve. In six of the eight patients, pain symptoms dramatically improved following regeneration—reflected as a collective decrease of 4.6 points in Visual Analog Scale pain scores.

Prologo believes that the interventional radiology skillset applied to nerve freezing has many applications for treatment of complex pain. “We are using this regeneration technique not only to manage nerve pain induced by trauma—but also for pudendal neuralgia, post mastectomy pain, post-surgical pain, and many other conditions historically managed with narcotics,” says Prologo. “Interventional radiologists can place these needles safely in precise locations all over the body, allowing access to pain generators that were previously unreachable and giving hope to patients who struggle with pain.”

Abstract LBA 1: Percutanelously induced neuroregeneration for the management of chronic painful mononeruopathies secondary to trauma. J. Prologo, N. Resnick, F. Prologo, E. Friedberg. Annual Scientific Meeting, June 11–16, 2022.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”